PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-alpha may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR-activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which induces ABCA1-promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This mechanism is pivotal in controlling intracellular lipid content and serves as a primary “gatekeeper” for reverse cholesterol transport in cells [23].”
From miR-223 accelerates lipid droplets clearance in microglia following spinal cord injury by upregulating ABCA1 (2024) · cites this paper as [23]
In the citing paper
“The activation of PPARα also accelerates reverse cholesterol transport (RCT) via increased expression of ABCA1 and ABCG1 transporters involved in cholesterol efflux from macrophages [29, 40].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [40]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630 · cited 1×
“, and this led to the suggestion that PPAR-activators may modulate foam-cell formation, a known atherogenic process characterized by cholesteryl-ester-droplet accumulation in the cytoplasm of macrophage”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899 · cited 1×
“Both PPAR-α and PPAR-γ are expressed in fully-differentiated human macrophages where they regulate genes implicated in the inflammatory response, modulate macrophage differentiation and promote TNF-α/IFN-γ–induced apoptosi”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“We treated these cells with either the PPAR-α ligand Wy14643 or the PPAR-γ ligand rosiglitazone at concentrations of 2–3 times their EC 50 values (Wy14643 EC 50 for human PPAR-αe25 μM and rosiglitazone EC 50 for human PPAR-γe43 nM”
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 1×
“Moreover, PPAR-α activation results in the transcriptional induction of CD36 expression in macrophage”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“The stimulatory role of PPAR-α activators on hepatic HDL production and apoAI expression is well-documente”
BackgroundSelf-citationMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591 · cited 1×
“We also show that both PPAR-α and PPAR-γ activators induce ABCA1 expression, possibly through their inductive effects on expression of LXR-α, a nuclear receptor activated by oxysterol”
Background
Cited by
Items 101–200 of 1,000
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice
Torra, I. P., Chinetti, G., Duval, C., Fruchart, J.-C., & Staels, B. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00002 · Cited by 210
Self-citationDaub, K., Langer, H., Seizer, P., Stellos, K., May, A. E., Goyal, P., Bigalke, B., Schönberger, T., Geisler, T., Siegel‐Axel, D., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6265fje · Cited by 207
PPARs and the Cardiovascular System
Hamblin, M., Chang, L., Fan, Y., Zhang, J., & Chen, Y. E. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2280 · Cited by 207
Vassiliou, E., & Farias-Pereira, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512032 · Cited by 202
“The isoforms PPAR-α and PPAR-γ induce cholesterol efflux by upregulating ABCA1 expression via LXR-α in macrophages [32].”
BackgroundSprecher, D. L., Massien, C., Pearce, G., Billin, A. N., Perlstein, I., Willson, T. M., Hassall, D. G., Ancellin, N., Patterson, S. D., Lobe, D. C., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252790.70572.0c · Cited by 201
Yanai, H., Adachi, H., Hakoshima, M., Iida, S., & Katsuyama, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015473 · Cited by 194
“In addition, PPAR α agonists promote HDL-mediated cholesterol efflux from macrophages via enhanced expression of ABCA1 [103].”
BackgroundDUVAL, C., MULLER, M., & KERSTEN, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.003 · Cited by 199
Ide, T., Shimano, H., Yoshikawa, T., Yahagi, N., Amemiya-Kudo, M., Matsuzaka, T., Nakakuki, M., Yatoh, S., Iizuka, Y., Tomita, S., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0191 · Cited by 199
Sidhu, J. S., Cowan, D., & Kaski, J.-C. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.04.001 · Cited by 197
DNA Methylation of Lipid-Related Genes Affects Blood Lipid Levels
Pfeiffer, L., Wahl, S., Pilling, L. C., Reischl, E., Sandling, J. K., Kunze, S., Holdt, L. M., Kretschmer, A., Schramm, K., Adamski, J., et al. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000804 · Cited by 194
Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.
Jasińska-Stroschein, M., Owczarek, J., & Orszulak–Michalak, D. (2007) · PubMed · Cited by 229
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
PPARγ and Atherosclerosis: Effects on Cell Growth and Movement
Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1201.100261 · Cited by 191
Regulation of reverse cholesterol transport and clinical implications
Rader, D. J. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00615-5 · Cited by 191
A role for PPARα in the control of SREBP activity and lipid synthesis in the liver
Knight, B. L., Hebbachi, A., Hauton, D., Brown, A.-M., Wiggins, D., Patel, D. D., & Gibbons, G. F. (2005) · Biochemical Journal · doi:10.1042/bj20041896 · Cited by 188
PPAR agonists: multimodal drugs for the treatment of type-2 diabetes
Gross, B., & Staels, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.004 · Cited by 186
Self-citationThe Effects of SGLT2 Inhibitors on Lipid Metabolism
Szekeres, Z., Toth, K., & Szabados, E. (2021) · Metabolites · doi:10.3390/metabo11020087 · Cited by 187
“PPAR-γ increases insulin sensitivity through increasing storage of fatty acids in fat cells, enhancing adiponectin release, inducing fibroblast growth factor 21 (FGF21) and upregulating the cluster of differentiation 36 (CD36) enzyme [35].”
BackgroundBioactive lipids in metabolic syndrome
Nagao, K., & Yanagita, T. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2007.12.002 · Cited by 185
Duez, H., Chao, Y.-S., Hernandez, M., Torpier, G., Poulain, P., Mundt, S., Mallat, Z., Teissier, E., Burton, C. A., Tedgui, A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206966200 · Cited by 186
Self-citationFu, Y., Luo, N., Lopes-Virella, M. F., & Garvey, W. T. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00305-2 · Cited by 185
ABC A-subfamily transporters: Structure, function and disease
Kaminski, W. E., Piehler, A., & Wenzel, J. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.01.011 · Cited by 183
Rubic, T., Trottmann, M., & Lorenz, R. L. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.09.014 · Cited by 182
Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis
Yuan, Y., Li, P., & Ye, J. (2012) · Protein & Cell · doi:10.1007/s13238-012-2025-6 · Cited by 181
The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor γ and Its Therapeutic Modulation
Gurnell, M., Savage, D. B., Chatterjee, V. K. K., & O’Rahilly, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030435 · Cited by 179
Babaev, V. R., Yancey, P. G., Ryzhov, S. V., Kon, V., Breyer, M. D., Magnuson, M. A., Fazio, S., & Linton, M. F. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000173413.31789.1a · Cited by 178
Identification of a subtype selective human PPARα agonist through parallel-array synthesis
Brown, P. J., Stuart, L. W., Hurley, K. P., Lewis, M. C., Winegar, D. A., Wilson, J. G., Wilkison, W. O., Ittoop, O. R., & Willson, T. M. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00188-3 · Cited by 177
PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism
BOCHER, V., PINEDA‐TORRA, I., FRUCHART, J., & STAELS, B. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04258.x · Cited by 178
Self-citationObesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Blaschke, F., Takata, Y., Caglayan, E., Law, R. E., & Hsueh, W. A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191663.12164.77 · Cited by 176
Preventive and Prophylactic Mechanisms of Action of Pomegranate Bioactive Constituents
Viladomiu, M., Hontecillas, R., Lu, P., & Bassaganya-Riera, J. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/789764 · Cited by 174
Fatty acids as gatekeepers of immune cell regulation
Yaqoob, P. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.10.002 · Cited by 176
Rosiglitazone: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Wagstaff, A. J., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262120-00007 · Cited by 175
“[89] PPARγ is expressed in human macrophages and rosiglitazone induces cholesterol removal from macrophage foam cells.[90] Rosiglitazone does not appear to affect monocyte/macrophage differentiation.”
Guan, Y. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000139067.83419.46 · Cited by 175
ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosis
Matsuo, M. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.11.005 · Cited by 174
Update on strategies to increase HDL quantity and function
Duffy, D., & Rader, D. J. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.94 · Cited by 169
Jones, D. C., Ding, X., & Daynes, R. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106908200 · Cited by 169
Thiazolidinediones: effects on insulin resistance and the cardiovascular system
Quinn, C. E., Hamilton, P. K., Lockhart, C. J., & McVeigh, G. E. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707452 · Cited by 166
Sato, O., Kuriki, C., Fukui, Y., & Motojima, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110158200 · Cited by 166
Macrophage Plasticity and Atherosclerosis Therapy
Lin, P., Ji, H.-H., Li, Y.-J., & Guo, S.-D. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.679797 · Cited by 162
“PPARα and PPARγ agonists may also promote macrophage cholesterol efflux via activating ABCA1 expression (Chinetti et al., 2001; Li et al., 2004).”
BackgroundNovel Roles of Liver X Receptors Exposed by Gene Expression Profiling in Liver and Adipose Tissue
Stulnig, T. M., Steffensen, K. R., Gao, H., Reimers, M., Dahlman-Wright, K., Schuster, G. U., & Gustafsson, J.-Å. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.6.1299 · Cited by 164
Pineda Torra, I., Jamshidi, Y., Flavell, D. M., Fruchart, J.-C., & Staels, B. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.5.0833 · Cited by 164
Self-citationActivation of TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis
Ma, L., Zhong, J., Zhao, Z., Luo, Z., Ma, S., Sun, J., He, H., Zhu, T., Liu, D., Zhu, Z., et al. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr245 · Cited by 162
Ricote, M., Valledor, A. F., & Glass, C. K. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000103951.67680.b1 · Cited by 162
ATP-binding cassette transporter A1 and cholesterol trafficking
Oram, J. F. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200208000-00004 · Cited by 161
Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs)
Sporn, M. B., Suh, N., & Mangelsdorf, D. J. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02100-1 · Cited by 159
Regulation and intracellular trafficking of the ABCA1 transporter
Santamarina-Fojo, S., Remaley, A. T., Neufeld, E. B., & Brewer, H. B. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30266-2 · Cited by 158
Self-citationAtheroprotective effects of (poly)phenols: a focus on cell cholesterol metabolism
Zanotti, I., Dall'Asta, M., Mena, P., Mele, L., Bruni, R., Ray, S., & Del Rio, D. (2015) · Food & Function · doi:10.1039/c4fo00670d · Cited by 156
Statin-fibrate combination therapy for hyperlipidaemia: a review
Wierzbicki, A. S., Mikhailidis, D. P., Wray, R., Schachter, M., Cramb, R., Simpson, W. G., & Byrne, C. B. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001668 · Cited by 155
PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Ahmed, W., Ziouzenkova, O., Brown, J., Devchand, P., Francis, S., Kadakia, M., Kanda, T., Orasanu, G., Sharlach, M., Zandbergen, F., et al. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01825.x · Cited by 153
Ricketts, M., Moore, D. D., Banz, W. J., Mezei, O., & Shay, N. F. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.11.008 · Cited by 177
Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
Barter, P. J., & Rye, K.-A. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.148817 · Cited by 153
Gallardo-Soler, A., Gómez-Nieto, C., Campo, M. L., Marathe, C., Tontonoz, P., Castrillo, A., & Corraliza, I. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0525 · Cited by 151
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Kersten, S. (2008) · PPAR Research · doi:10.1155/2008/132960 · Cited by 149
“No PPRE has yet been identified in the human or mouse ABCA1 gene, suggesting that ABCA1 may not be a direct PPARα target.”
InfluentialLipoproteins, macrophage function, and atherosclerosis: Beyond the foam cell?
Rader, D. J., & Puré, E. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.03.005 · Cited by 167
“Treatment of macrophages with synthetic ligands to PPARα, PPARγ, and PPARδ have been reported to result in promotion of cholesterol efflux pathways in vitro (Chawla et al., 2001; Chinetti et al., 2001; Oliver et al., 2001).”
BackgroundForcheron, F., Cachefo, A., Thevenon, S., Pinteur, C., & Beylot, M. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3486 · Cited by 148
Anthocyanins Induce Cholesterol Efflux from Mouse Peritoneal Macrophages
Xia, M., Hou, M., Zhu, H., Ma, J., Tang, Z., Wang, Q., Li, Y., Chi, D., Yu, X., Zhao, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505047200 · Cited by 148
ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease
Wollmer, M. A., Streffer, J. R., Lütjohann, D., Tsolaki, M., Iakovidou, V., Hegi, T., Pasch, T., Jung, H. H., von Bergmann, K., Nitsch, R. M., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00094-5 · Cited by 158
“from the inner to the outer layer of the cell membrane, thus enabling the binding of cholesterol to apolipoproteins [3,4,27,29].”
BackgroundA closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice
Rössger, K., Charpin-El-Hamri, G., & Fussenegger, M. (2013) · Nature Communications · doi:10.1038/ncomms3825 · Cited by 145
PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases
Lin, Y., Wang, Y., & Li, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1074911 · Cited by 182
“Hepatic PPARa activity controls the expression of apolipoprotein, as functional PPRE has been identified in the promoters of the LPL, APOA5, APOA1, and APOA2 genes (16), whereas PPARa regulates ABCA1 in macrophage and intestine.”
BackgroundInfluentialChoudhury, R. P., Lee, J., & Greaves, D. R. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0195 · Cited by 160
MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation
Ying, W., Tseng, A., Chang, R. C.-A., Morin, A., Brehm, T., Triff, K., Nair, V., Zhuang, G., Song, H., Kanameni, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81656 · Cited by 144
PPARγ is a nexus controlling alternative activation of macrophages via glutamine metabolism
Nelson, V. L., Nguyen, H. C. B., Garcìa-Cañaveras, J. C., Briggs, E. R., Ho, W. Y., DiSpirito, J. R., Marinis, J. M., Hill, D. A., & Lazar, M. A. (2018) · Genes & Development · doi:10.1101/gad.312355.118 · Cited by 141
MicroRNA: Dynamic Regulators of Macrophage Polarization and Plasticity
Self-Fordham, J. B., Naqvi, A. R., Uttamani, J. R., Kulkarni, V., & Nares, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01062 · Cited by 140
Local cholesterol metabolism orchestrates remyelination
Berghoff, S. A., Spieth, L., & Saher, G. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.01.001 · Cited by 137
“However, several signaling routes beyond LXR that also compromise lipid trafficking and efflux can be involved in the transition of phagocytes to foam cells, for example, PPAR signaling [71,72].”
BackgroundFrambach, S. J. C. M., de Haas, R., Smeitink, J. A. M., Rongen, G. A., Russel, F. G. M., & Schirris, T. J. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.017897 · Cited by 137
“PPARs have been associated with an increased ABCA1 expression and consequently enhanced HDL biogenesis in vitro and in vivo (Chinetti et al., 2001; Ogata et al., 2009).”
BackgroundInfluentialSertznig, P., Seifert, M., Tilgen, W., & Reichrath, J. (2008) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200809010-00002 · Cited by 150
Cross-Tissue Regulatory Gene Networks in Coronary Artery Disease
Talukdar, H. A., Foroughi Asl, H., Jain, R. K., Ermel, R., Ruusalepp, A., Franzén, O., Kidd, B. A., Readhead, B., Giannarelli, C., Kovacic, J. C., et al. (2016) · Cell Systems · doi:10.1016/j.cels.2016.02.002 · Cited by 136
Peroxisome proliferator-activated receptor-$gamma; ligands as cell-cycle modulators
Theocharis, S., Margeli, A. P., Vielh, P. R., & Kouraklis, G. P. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.004 · Cited by 139
Flavell, D. M., Jamshidi, Y., Hawe, E., Pineda Torra, I., Taskinen, M.-R., Frick, M. H., Nieminen, M. S., Kesäniemi, Y. A., Pasternack, A., Staels, B., et al. (2002) · Circulation · doi:10.1161/01.cir.0000012145.80593.25 · Cited by 134
Self-citationLiver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation
Bakiri, L., Hamacher, R., Graña, O., Guío-Carrión, A., Campos-Olivas, R., Martinez, L., Dienes, H. P., Thomsen, M. K., Hasenfuss, S. C., & Wagner, E. F. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160935 · Cited by 133
“…decreased LXRα expression and activity in liver cells occurs through direct binding of PPARγ to the LXRα promoter, as shown in human macrophages (Chinetti et al., 2001; Laffitte et al., 2001), or rather, as proposed by Yoshikawa et al. (2003), through competitive reduction of LXR/RXR dimers,…”
BackgroundThe complications of promiscuity: endocannabinoid action and metabolism
Alexander, S. P. H., & Kendall, D. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707456 · Cited by 133
“ABCA1 transporter protein in human macrophage foam cells (Chinetti et al., 2001), while gene disruption of PPARg reduced ABCA1 and ABCG1 expression in mouse macrophage foam cells (Akiyama et al.”
BackgroundLiver X receptors (LXR) as therapeutic targets in dyslipidemia
Bełtowski, J. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00062.x · Cited by 132
Hennuyer, N., Duplan, I., Paquet, C., Vanhoutte, J., Woitrain, E., Touche, V., Colin, S., Vallez, E., Lestavel, S., Lefebvre, P., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.003 · Cited by 132
Self-citationMetabolic programming of macrophage functions and pathogens control
Koo, S.-J., & Garg, N. J. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101198 · Cited by 132
“The PPAR-α activation has been shown to improve the cholesterol efflux and reduce lipid accumulation in Mφ [86,87], which are key mechanisms in reducing lipid-laden inflammatory Mφ in atherosclerotic plaques.”
Bonfield, T. L., Farver, C. F., Barna, B. P., Malur, A., Abraham, S., Raychaudhuri, B., Kavuru, M. S., & Thomassen, M. J. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0148oc · Cited by 131
Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system
Kim, T., & Yang, Q. (2013) · World Journal of Cardiology · doi:10.4330/wjc.v5.i6.164 · Cited by 139
Robinson, E., & Grieve, D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.003 · Cited by 138
Targeted PPARγ deficiency in alveolar macrophages disrupts surfactant catabolism
Baker, A. D., Malur, A., Barna, B. P., Ghosh, S., Kavuru, M. S., Malur, A. G., & Thomassen, M. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m001651 · Cited by 128
Ghosh, A., Jana, M., Modi, K., Gonzalez, F. J., Sims, K. B., Berry-Kravis, E., & Pahan, K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610659 · Cited by 130
Peroxisome Proliferator-Activated Receptor γ: Implications for Cardiovascular Disease
Hsueh, W. A., & Bruemmer, D. (2004) · Hypertension · doi:10.1161/01.hyp.0000113626.76571.5b · Cited by 137
Hsueh, W. A., & Law, R. E. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00610-6 · Cited by 148
Regulation of Macrophage Cholesterol Efflux through Hydroxymethylglutaryl-CoA Reductase Inhibition
Argmann, C. A., Edwards, J. Y., Sawyez, C. G., O'Neil, C. H., Hegele, R. A., Pickering, J. G., & Huff, M. W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502761200 · Cited by 129
Low-Intensity Exercise Exerts Beneficial Effects on Plasma Lipids via PPARγ
BUTCHER, L. R., THOMAS, A., BACKX, K., ROBERTS, A., WEBB, R., & MORRIS, K. (2008) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31816c091d · Cited by 128
Barbier, O., Villeneuve, L., Bocher, V., Fontaine, C., Torra, I. P., Duhem, C., Kosykh, V., Fruchart, J.-C., Guillemette, C., & Staels, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300749200 · Cited by 128
Self-citationMoreno, P., & Fuster, V. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.077 · Cited by 133
Bishop‐Bailey, D., & Wray, J. A. (2003) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(03)00003-0 · Cited by 151
Saha, S. A., Kizhakepunnur, L. G., Bahekar, A., & Arora, R. R. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.011 · Cited by 137
Peroxisome proliferator-activated receptors in cutaneous biology
Kuenzli, S., & Saurat, J. ‐. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05532.x · Cited by 134
Nuclear Receptor Signaling in the Control of Cholesterol Homeostasis: Have the Orphans Found a Home?
Ory, D. S. (2004) · Circulation Research · doi:10.1161/01.res.0000143422.83209.be · Cited by 128
Calkin, A. C., Forbes, J. M., Smith, C. M., Lassila, M., Cooper, M. E., Jandeleit-Dahm, K. A., & Allen, T. J. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000177813.99577.6b · Cited by 128
PPARs and other nuclear receptors in inflammation
RIZZO, G., & Fiorucci, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.012 · Cited by 139
Uehara, Y., Engel, T., Li, Z., Goepfert, C., Rust, S., Zhou, X., Langer, C., Schachtrup, C., Wiekowski, J., Lorkowski, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2922 · Cited by 139
Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism
Fruchart, J. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02149-x · Cited by 138
Self-citationFibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice
Mardones, P., Pilon, A., Bouly, M., Duran, D., Nishimoto, T., Arai, H., Kozarsky, K. F., Altayó, M., Miquel, J. F., Luc, G., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211627200 · Cited by 124
Self-citationBardini, G., Rotella, C. M., & Giannini, S. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.82 · Cited by 138
Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes
Grip, O., Janciauskiene, S. M., & Lindgren, S. C. (2002) · Inflammation Research · doi:10.1007/bf02684000 · Cited by 140
Regulation of High-Density Lipoprotein Metabolism
Rye, K., & Barter, P. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.300632 · Cited by 139
Assembly of High-Density Lipoprotein
Yokoyama, S. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000195789.39418.e8 · Cited by 121
Sertznig, P., Seifert, M., Tilgen, W., & Reichrath, J. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20998 · Cited by 121
“(Muller-Decker et al., 1999; Chinetti et al., 2001).”
On the mechanism for PPAR agonists to enhance ABCA1 gene expression
Ogata, M., Tsujita, M., Hossain, M. A., Akita, N., Gonzalez, F. J., Staels, B., Suzuki, S., Fukutomi, T., Kimura, G., & Yokoyama, S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.008 · Cited by 120
Self-citationGiacomini, I., Gianfanti, F., Desbats, M. A., Orso, G., Berretta, M., Prayer‐Galetti, T., Ragazzi, E., & Cocetta, V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682911 · Cited by 133
Metadata
- Authors
- Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J.-C., Clavey, V., & Staels, B.
- Affiliations
- Inserm (FR)
- National Institutes of Health (US)
- Sanofi (France) (FR)
- Corresponding author
- Staels, Bart
- Venue
- Nature Medicine
- Published
- 2001-01
- Volume
- 7
- Issue
- 1
- Pages
- 53-58
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1524478189
- Cited by
- 1,170
- References
- 39
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 31 · 2023: 41 · 2022: 25 · 2021: 28 · 2020: 30 · 2019: 20 · 2018: 29 · 2017: 31 · 2016: 38 · 2015: 33 · 2014: 50 · 2013: 37 · 2012: 38
- FWCI
- 99.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARα, PPARγ, ABCA1, cholesterol efflux, foam cells, macrophages, reverse cholesterol transport, liver X receptor alpha, apolipoprotein A-I, Tangier disease, acetylated LDL, CD36, THP-1 macrophages
- MeSH terms
- Base Sequence, Biological Transport, Cells, Cultured, Cholesterol, Foam Cells, Humans, Transcription Factors, DNA Primers, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.